Lumera Licenses Helix Biopharma Technology in Bid to Enter Protein Array Market

Lumera said this week that it has acquired the exclusive rights to protein surface chemistry from Helix Biopharma in order to further its development of a proteomic microarray.

Lumera said it will combine Helix Biopharma’s Heterodimer Protein Technology with its own NanoCapture Array technology. The integrated technologies will allow Lumera to produce and capture proteins on a silicon surface while keeping the proteins fully functional, the company said.